CapsoVision, Inc. (NASDAQ:CV) Short Interest Update

Key Points

• CapsoVision, Inc. (NASDAQ:CV) experienced a significant increase in short interest in September, rising by 296.2% from 10,600 shares to 42,000 shares.
• The company reported earnings of (\$2.02) per share, missing estimates, but had a revenue of \$3.32 million which exceeded expectations.
• Analysts currently have a consensus rating of "Moderate Buy" for CapsoVision, with an average target price of \$5.50 per share.

CapsoVision, Inc. (NASDAQ:CV - Get Free Report) saw a large increase in short interest in September. As of September 30th, there was short interest totaling 42,000 shares, an increase of 296.2% from the September 15th total of 10,600 shares. Based on an average trading volume of 53,900 shares, the short-interest ratio is presently 0.8 days. Approximately 0.2% of the shares of the stock are short sold. Approximately 0.2% of the shares of the stock are short sold. Based on an average trading volume of 53,900 shares, the short-interest ratio is presently 0.8 days.

CapsoVision Trading Up 5.0%

NASDAQ:CV opened at $4.84 on Friday. The company has a 50-day moving average price of $4.25. CapsoVision has a 1-year low of $3.43 and a 1-year high of $5.72.

CapsoVision (NASDAQ:CV - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($2.02) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($1.91). The business had revenue of $3.32 million for the quarter, compared to the consensus estimate of $3.20 million.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CV. Roth Capital set a $6.00 price objective on shares of CapsoVision and gave the company a "buy" rating in a research note on Monday, July 28th. Weiss Ratings reaffirmed a "sell (e-)" rating on shares of CapsoVision in a research note on Wednesday, October 8th. Benchmark began coverage on shares of CapsoVision in a research note on Monday, July 28th. They set a "speculative buy" rating and a $5.00 price objective for the company. Finally, Wall Street Zen raised shares of CapsoVision to a "hold" rating in a research note on Sunday, July 13th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $5.50.

CapsoVision Company Profile

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.